Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
24.80
-0.15 (-0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
24.80
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:47 PM EDT
Arcus Biosciences Employees
Arcus Biosciences had 601 employees as of December 31, 2025. The number of employees decreased by 26 or -4.15% compared to the previous year.
Employees
601
Change (1Y)
-26
Growth (1Y)
-4.15%
Revenue / Employee
$410,982
Profits / Employee
-$587,354
Market Cap
3.12B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Denali Therapeutics | 503 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
| Relay Therapeutics | 192 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
RCUS News
- 4 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 days ago - What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
- 7 days ago - Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates - Business Wire
- 7 weeks ago - Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 2 months ago - Arcus Biosciences Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 2 months ago - Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer - Business Wire